Chronic Lymphocytic Leucemia Recruiting Phase 2 Trials for Bendamustine (DB06769)

IndicationStatusPhase
DBCOND0074005 (Chronic Lymphocytic Leucemia)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02445131Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)Treatment